2-[3-(4-cyanobenzoyl)indolizin-1-yl]-N-(3-methyl-1,2-thiazol-5-yl)-2-oxoacetamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-[3-(4-cyanobenzoyl)indolizin-1-yl]-N-(3-methyl-1,2-thiazol-5-yl)-2-oxoacetamide
• 化学式: C₂₂H₁₄N₄O₃S
• 分子量: 414.4
• InChiKey: DTIWPWUMSHPLOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  133
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• 1-Glyoxylamide indolizines for treating lung and ovarian cancer
  申请人：Koya Keizo

  公开号：US20050272766A1

  公开（公告）日：2005-12-08

  A method of treating a subject having lung cancer or ovarian cancer, comprising administering to the subject an effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt, solvate, or polymorph thereof: Ring A is substituted or unsubstituted and optionally fused to an aryl group. Z 1 and Z 2 are independently ═O, ═S, ═N—OR 12 or ═NR 12 R 1 and R 2 are independently —H, an aliphatic group, a substituted aliphatic group, an unsubstituted non-aromatic heterocylic group, a substituted non-aromatic heterocylic group, an aryl group or a substituted aryl group, provided that R 1 and R 2 are not both —H. Alternatively, —NR 1 R 2 , taken together, is a substituted or unsubstituted non-aromatic nitrogen-containing heterocyclic group or a substituted or unsubstituted nitrogen-containing heteroaryl group. R 3 is a substituted or unsubstituted aryl group or a substituted or unsubstituted aliphatic group. X is a covalent bond, —C(R 4 R 5 )—, —N(R 4 )—, —O—, —S—, —S(O)—, —S(O) 2 —, —C(═O)—, —C(═O)—N(R 4 )—, or —N(R 4 )—C(═O)—. R 4 and R 5 are independently —H or a substituted or unsubstituted aliphatic group. R 12 is —H or a substituted or unsubstituted alkyl group.

  一种治疗肺癌或卵巢癌受试者的方法，包括向受试者施用有效量的结构式（I）所代表的化合物或其药学上可接受的盐、溶液或多晶型物： 环 A 是取代或未取代的，可选择与芳基融合。 Z 1 和 Z 2 独立地为═O、═S、═N-OR 12 或═NR 12 R 1 和 R 2 独立地为-H、脂肪族基团、取代的脂肪族基团、未取代的非芳杂环族基团、取代的非芳杂环族基团、芳基或取代的芳基，条件是 R 1 和 R 2 并非都是-H。或者，-NR 1 R 2 是取代或未取代的非芳香族含氮杂环基团或取代或未取代的含氮杂芳基。 R 3 是取代或未取代的芳基或取代或未取代的脂肪族基团。 X 是共价键、-C(R 4 R 5 )-，-N(R 4 )-，-O-，-S-，-S(O)-，-S(O) 2 -，-C(═O)-，-C(═O)-N(R 4 )-，或-N(R 4 )-C(═O)-。 R 4 和 R 5 独立地为-H 或取代或未取代的脂肪族基团。 R 12 是-H 或取代或未取代的烷基。
• [EN] 1-GLYOXYLAMIDE INDOLIZINES FOR TREATING LUNG AND OVARIAN CANCER<br/>[FR] 1-GLYOXYLAMIDE INDOLIZINES DESTINES AU TRAITEMENT DU CANCER DU POUMON OU DE L'OVAIRE
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2005099824A1

  公开（公告）日：2005-10-27

  A method of treating a subject having lung cancer or ovarian cancer, comprising administering to the subject an effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt, solvate, or polymorph thereof: Ring A is substituted or unsubstituted and optionally fused to an aryl group. Z1 and Z2 are independently=O, =S, =N-OR12 or =NR12, R1 and R2 are independently -H, an aliphatic group, a substituted aliphatic group, an unsubstituted non-aromatic heterocylic group, a substituted non-aromatic heterocylic group, an aryl group or a substituted aryl group, provided that R1 and R2 are not both -H. Alternatively, -NR1R2, taken together, is a substituted or unsubstituted non-aromatic nitrogen-containing heterocyclic group or a substituted or unsubstituted nitrogen-containing heteroaryl group. R3 is a substituted or unsubstituted aryl group or a substituted or unsubstituted aliphatic group. X is a covalent bond, -C(R4R5)-, -N(R4)-, -O-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -C(=O)-N(R4)-, or -N(R4)-C(=O)-. R4 and R5 are independently -H or a substituted or unsubstituted aliphatic group. R12 is -H or a substituted or unsubstituted alkyl group.